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Graft-versus-host disease (GVHD) is the major life-threatening complication after allogeneic hematopoietic
stem cell transplantation (allo-HSCT), developing in 35%-70% of all allo-HSCT recipients despite immuno-
suppressive prophylaxis. The recent application of proteomic tools that allow screening for differentially
expressed or excreted proteins in body ﬂuids could possibly identify speciﬁc biomarkers for GVHD. Whole
saliva is highly attractive for noninvasive specimen collection. In the present study, we collected saliva
specimens from 40 consecutives patients who underwent allo-HSCT between December 2008 and March
2011 at our institution. The specimens were analyzed by HPLC coupled to electrospray-ionization mass
spectrometry. Variable expression of S100 protein family members (S100A8, S100A9, and S100A7) was
detected. Fourteen of 23 patients with GVHD demonstrated the presence of S100A8, compared with only 2
patients without GVHD and 0 patients in the control group (P ¼ .001). S100A7 was detectable in 11 of the 23
patients with GVHD but was absent in the other 2 groups (P ¼ .0001). S100A9-short was detected in 20
patients with GVHD, in 9 patients without GVHD, and in 8 healthy volunteers (P ¼ .01) Further studies are
needed to clarify the role of these proteins as a marker of GVHD or as an index of mucosal inﬂammation.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
HSCT) is a potential curative treatment for hematopoietic
malignancies, hematopoietic failure, and autoimmune
disease. Despite enormous advances in allo-HSCT practice,
signiﬁcant challenges remain that limit more widespread
application of this treatment. Although nonmyeloablative
conditioning regimens have decreased treatment-related
mortality, major complications, such as graft-versus-host
disease (GVHD) and severe infection, still occur [1]. Depend-
ing on the type of transplantation, the immunosuppressive
treatment, and underlying diseases, between 35% and 70% of
patients develop GVHD after allo-HSCT, and more than 35%
of these patients require immunosuppressive therapy [2].
Currently, the diagnosis of acute GVHD (aGVHD) is based
mainly on clinical parameters, including skin rash, diarrhea,
elevated serum liver enzyme levels, and others. Differential
diagnosis of GVHD depends on organ biopsy analyses to
distinguish GVHD from other common complications after
HSCT, including bacterial and viral infections and
chemotherapyeinduced toxicities [3]. To date, there is no
validated diagnostic test for aGVHD, although several studies
have identiﬁed multiple blood proteins as potential
biomarkers; however, differences in any single protein lack
sufﬁcient speciﬁcity and sensitivity to be of clinical use, andedgments on page 892.
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13.03.011so a GVHD diagnosis is still conﬁrmed by invasive procedures
[4-8].
The study of proteomics has evolved rapidly over the past
decade. High-throughput MS approaches coupled to
different separation techniques, including HPLC and bidi-
mensional gel electrophoresis have been applied to several
human diseases with the aim of replacing or complementing
traditional tools for disease diagnosis and monitoring of
disease activity or response to therapy. Proteomic techniques
have speciﬁc application in the search for biomarkers and
therapeutic targets, especially in oncologic and autoimmune
diseases [9-15].
The study of proteomic patterns of biological samples in
patients affected by GVHD has expanded rapidly over the last
few years, with the aim of identifying speciﬁc and sensitive
markers of GVHD with predictive and prognostic value.
Plasma and urine are the biological ﬂuids principally inves-
tigated for proteomic proﬁling in studies of patients with and
without GVHD after allo-HCT [16-20]. Few studies have
examined the analysis of salivary proteins, despite the fact
that the oral cavity is often involved in the pathology of
GVHD [21-24]. Chronic GVHD affects the oral mucosa with
a frequency second only to that of skin, causing signiﬁcant
morbidity [25]. Major oral clinical manifestations include
mucositis, xerostomia, gingivitis, erythema, inﬂammation,
salivary gland dysfunction, pain and taste disorders; oral
ﬁndings include lichen planuselike changes, hyperkeratotic
plaques, mucosal atrophy, and pseudomembranous ulcera-
tion in patterns reminiscent of autoimmune diseases such as
lichen planus, lupus systemic sclerosis, and Sjogren
syndrome [26-28].Transplantation.
Table 1
Patient Characteristics
Number of Patients 40
Males/females 17/23
Diagnoses 20 acute myelogenous leukemia, 6 acute
lymphoblastic leukemia, 5 non-Hodgkin
lymphoma, 2 Hodgkin lymphoma, 1 chronic
lymphocytic leukemia, 2 myelodysplastic
syndrome, 1 idiopatic myeloﬁbrosis, 3 multiple
myeloma
Disease status 17 complete remission, 5 partial remission, 2
progressive disease, 3 refractory disease, 11
relapsed disease, 2 stable disease
Donors 28 sibling HLA-matched donors; 12 unrelated
HLA-matched donors
Conditioning
regimens
13 myeloablative; 27 reduced-intensity
Hematopoietic stem
cell source
37 peripheral blood, 1 bone marrow, 2 cord
blood
CD34þ cells,  106/kg,
median (range)
7  106/kg (1.47-17  106/kg)
GVHD prophylaxis 20 CSA þ methotrexate, 14 CSA þ
mycophenolate mofetil, 3 CSA þ Campath,
1 CSA, 2 no GVHD prophylaxis
P. Chiusolo et al. / Biol Blood Marrow Transplant 19 (2013) 888e892 889Saliva is an attractive diagnostic ﬂuid, providing several
key advantages, including easy and noninvasive sample
collection, ready processing, and fewer proteins than plasma.
A body ﬂuid of a very complex and speciﬁc composition
devoted to the protection of the oral cavity, saliva includes
organic and inorganic solutes and speciﬁc peptides and
proteins containing components of both innate and adaptive
immunity. Some of these proteins have speciﬁc antimicro-
bial, immunomodulatory, and anti-inﬂammatory activities
[29]. Proteins with these functions are differently expressed
in the saliva of patients affected by Sjogren syndrome; in
particular, a-defensins and some members of the S100A
protein family (S100A9 and S100A7) were found to be up-
regulated in both saliva and tears of patients with Sjogren
syndrome [13,30-32].
Sjogren syndrome is a chronic inﬂammatory autoimmune
disease characterized by functional inhibition of autonomic
neurotransmission to lacrimal and salivary glands and inﬁl-
tration of the exocrine glands by effector T cells, leading to
qualitatively altered and diminished or absent glandular
secretion with clinical analogies to the sicca syndrome
affecting patients with GVHD, with xerostomia and xeroph-
talmia [33]. Thus, in our evaluation of changes in salivary
proteins after allo-HSCT, particularly in patients with GVHD,
we supposed that these changes would be similar to those
seen in patients with Sjogren syndrome. Consequently, we
performed salivary proteome analysis in patients undergoing
allo-HSCT, with the aim of comparing those with GVHD and
those without GVHD. A group of healthy subjects was also
enrolled to serve as a control. Speciﬁcally, using
a HPLCeelectrospray-ionization mass spectrometry (ESI-
MS)ebased approach, we investigated the levels of the
following proteins with known roles in inﬂammation, repair
of tissue damage, and innate and adaptive immunity:
a-defensins 1e4, thymosins b4 and b10, and S100A family
proteins S100A8, 4 isoforms of S100A9 (short, long, and
corresponding phosphorylated forms), 2 isoforms of S100A7
(D27 and E27), and S100A12.
PATIENTS AND METHODS
Patients
Subjects enrolled for the study were 40 consecutive patients who
underwent allo-HSCT at Hematology Department, Università Cattolica S.Cuore between December 2008 and March 2011. The group included 17
males (43%) and 23 females (57%), with a median age of 46 years (range, 14
to 65 years), affected by the following hematologic diseases: 20 (50%) with
acute myelogenous leukemia, 6 (15%) with acute lymphoblastic leukemia, 5
(12.5%) with non-Hodgkin lymphoma, 2 (5%) with Hodgkin lymphoma, 1
(2.5%) with chronic lymphocytic leukemia, 2 (5%) with myelodysplastic
syndrome, 1 (2.5%) with idiopatic myeloﬁbrosis, and 3 (7.5%) with multiple
myeloma.
Disease status at the time of allo-HSCT was 17 patients (42.5%) in
complete remission, 5 (12.5%) in partial remission, 2 (5%) with progressive
disease, 3 (7.5%) with refractory disease, 11 (27.5%) with relapsed disease,
and 2 (5%) with stable disease. Thirteen of the patients (32.5%) received
a myeloablative conditioning regimen before allo-HSCT, and 27 patients
(67.5%) received a reduced-intensity conditioning regimen. Stem cell grafts
were obtained from sibling donors for 28 patients and from unrelated
donors for 12 patients. GVHD prophylaxis was provided with cyclosporine
(CSA) andmethotrexate in 20 patients, CSA andmycophenolatemofetil in 14
patients, CSA and Campath in 3 patients, and CSA in 1 patient; 2 patients
received no GVHD prophylaxis (Table 1). Eighteen normal healthy subjects
(6 males and 12 females), with a median age of 35 years (range, 25 to
50 years), were included as controls. Saliva samples were obtained after
informed consent from each patient for use in biological studies.Sample Collection
Whole human saliva was collected every 30 days and at the onset of
GVHD in the ﬁrst 100 days after allo-HSCT, in accordance with a standard
study protocol. Donors did not eat or drink anything in the 30 minutes
before collection, which was performed between 10:00 and 12:00 a.m.
Whole salivawas collectedwith a soft plastic aspirator connected to a plastic
tube. An acidic solution (0.2% triﬂuoroacetic acid [TFA]) was immediately
added to the saliva samples at a 1:1 vol/vol ratio, and the resulting solution
was centrifuged at 8000  g for 5 minutes at 4 C. The acidic supernatant
was separated from the precipitate and either immediately analyzed with
the HPLCeESI-MS apparatus or stored at 80C until analysis. In the GVHD
group, samples were collected at the onset of complications, before the
initiation of steroid therapy. All patients developed oral cavity manifesta-
tions of GVHD, such as xerostomia, erythema, lichen planus-like changes,
hyperkeratotic plaques, mucosal atrophy, and pseudomembranous ulcera-
tions. In the other group, saliva samples were collected every 30 days during
the ﬁrst 100 days after allo-HSCT.HPLCeESI-MS Analysis
The HPLCeESI-MS apparatus was a Surveyor HPLC system (Thermo
Fisher, San Jose, CA) equipped with a photodiode array detector and con-
nected by a T splitter to a Thermo Fisher LCQ Deca XP Plus electrospray-
ionization/ion-trap mass spectrometer (split ratio 2:1) with a Vydac C8
chromatographic column (Vydac, Hesperia, CA) with 5 mm particle diameter
(column dimensions, 150  2.1 mm). The following solutions were used for
reversed-phase HPLCeESI-MS analysis: 0.056% (vol/vol) aqueous TFA
(eluent A) and 0.05% (vol/vol) TFA in 80/20 acetonitrile/water (eluent B). The
ﬂow rate was 0.30 mL/min. Salivary proteins were eluted using a linear
gradient from 0 to 55% of B in 40 minutes.Qualitative and Quantitative Data Analysis
The following proteins were analyzed: a-defensins 1e4, thymosins b4
and b10, and S100A family proteins S100A8, 4 isoforms of S100A9 (short,
long, and corresponding phosphorylated forms), 2 isoforms of S100A7 (D27
and E27 isoforms), and S100A12. These proteins have been identiﬁed and
characterized in previous studies [34,35].
Label-free quantiﬁcation of proteinswas based on themeasure of area of
the reversed-phase HPLCeESI-MS extracted ion current (XIC) peaks. Under
constant analytical conditions, the area of the extracted ion current peaks is
proportional to the peptide/protein concentration [34,36].Reagents
All general chemicals and reagents were of analytical grade and were
purchased from Farmitalia-Carlo Erba (Milan, Italy), Merck (Darmstadt,
Germany), and Sigma-Aldrich (St Louis, MO).Data Analysis
Datawere analyzedwith theMann-WhitneyU test and one-way ANOVA
using SPSS 16.0 (SPSS, Chicago, IL) and Prism software (Graph-Pad, San
Diego, CA). Statistical analysis was considered signiﬁcant at a P value of<.05
(2-tailed tests).
Table 2
Experimental Average Mass Values, Swiss Prot Identiﬁcation Codes, and Posttranslational Modiﬁcations of the Peptides and Proteins Analyzed in this Study
Protein MAV exp, Da Swiss Prot Code Posttranslational Modiﬁcation
a-defensin 1 3442.0  0.5 P59665 3 S-S
a-defensin 2 3371.0  0.5 P59665/6 3 S-S
a-defensin 3 3486.1  0.5 P59666 3 S-S
a-defensin 4 3707.8  0.5 P12838 3 S-S
Thymosin b4 4963.5  0.5 P62328 Acetyl (N-term)
Thymosin b10 4934.5  0.5 P63313 Acetyl (N-term)
S100A8 (calgranulin A) 10,834  1 P05109 d
S100A9 (calgranulin B) short 12,689  1 P06702 Acetyl, MTCKM missing (N-term)
S100A9 (calgranulin B) short P 12,769  1 P06702 Acetyl, MTCKM missing (N-term), phosphorylation (T108)
S100A9 (calgranulin B) long 13,153  1 P06702 Acetyl, M missing (N-term)
S100A9 (calgranulin B) long P 13,233  1 P06702 Acetyl, M missing (N-term), phosphorylation (T112)
S100A12 (calgranulin C) 10,444  1 P80511 M missing (N-term)
S100A7 (psoriasin D27) 11,368  1 P31151 Acetyl, M missing (N-term), E27/ D
S100A7 (psoriasin E27) 11,382  1 P31152 Acetyl, M missing (N-term)
MAV exp indicates experimental average mass value; S-S, disulﬁde bridge.
Figure 1. Levels of S100A8 for the 3 groups, expressed as XIC peak area.
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Patient Characteristics
Patients received grafts with a median CD34þ stem cell
dose of 7.0  106/kg (range, 1.47 to 17  106/kg). After
allo-HSCT, the median time to neutrophil engraftment at
a level of >0.5  109/L was 16 days (range, 1 to 34 days), and
that to a level of >1.0  109/L was 18 days (range, 8 to
34 days). The median time to spontaneous platelet recovery
at >20  109/L was 12 days (range, 2 to 38 days), and that
to>50  109/L was 14 days (range, 1 to 185 days). During the
ﬁrst 100 days after allo-HSCT, sepsis was microbiologically
documented in 14 patients (35%), whereas 13 patients pre-
sented with fever of unknown origin (32.5%). Twenty-ﬁve
patients (62.5%) developed cytomegalovirus reactivation at
a median time of 45 days (range, 5 to 200 days) after trans-
plantation, with a median maximum number of 4130 viral
genome copies/mL (range, 800 to 583.000 copies/mL). These
included 15 of 23 patients (65%) in the GVHD group and 10 of
17 patients (58%) in the other group. All patients received
preemptive antiviral therapy with gancyclovir.
Twenty-three patients (57%) developed aGVHD, at
a median time of 50 days (range, 10 to 97 days) after allo-
HSCT. In 5 of these patients, symptoms resolved after treat-
ment. Nine patients died early, at a median time of 2 months
(range, 1 to 3 months) after allo-HSCT, for a transplantation-
related mortality of 23% by 100 days posttransplantation.
Twenty patients (50%) had chronic GVHD, 8 with classic
chronic GVHD developing at amedian of 152 days (range,100
to 927 days) after allo-HSCT, and the other 12with an overlap
syndrome. All patients exhibited oral cavity manifestations
of GVHD. GVHD was diagnosed based on the Seattle criteria
[37,38].
Proteomic Analysis of Salivary Samples
HPLCeESI-MS analysis of whole human saliva detected
and quantiﬁed the following peptides/proteins: a-defensins
1e4, thymosins b4 and b10, and S100A8, S100A9, S100A12,
and S100A7 proteins [34,35]. Average mass values and the
various posttranslational modiﬁcation derivatives of the
proteins investigated are reported in Table 2. S100A proteins
analyzed included 2 isoforms of S100A7 presenting a residue
of glutamic acid or aspartic acid in position 27 (E27 and D27
isoforms), and 4 isoforms of S100A9 corresponding to short
and long phosphorylated and nonphosphorylated forms. The
long form of S100A9 is generated from the pro-protein by
loss of the N-terminal methionine residue followed by
acetylation, and phopshorylation may occur at thepenultimate threonine residue. In the short form of S100A9,
removal of the 5 N-terminal amino acid residues is followed
by acetylation. This form also may be phosphorylated at the
penultimate threonine residue.
The XIC procedure allowed measurement of the relative
amounts of the peptises/proteins in the study subjects, who
were divided into 3 groups: a group of 23 patients who
developed aGVHD after allo-HSCT, a group of 17 patients
without GVHD, and a group of 18 healthy controls matched
for age.
No differences in levels of the defensins and thymosin b4
were detected among the 3 groups. In contrast, statistically
signiﬁcant differences in the frequency and levels of S100A8,
S100A9-short, and S100A7 were found among the groups.
S100A8 was detected in 14 patients in the group with GVHD,
with a mean XIC peak area value of 3.50 108 (SD, 9.9 108),
compared with only 2 patients in the group without GVHD,
with a mean value of 2.46  108 (SD, 9.9  108) and none in
the control group. A statistically signiﬁcant difference among
the 3 groups in terms of frequency (P ¼ .001) and levels of
detection (P ¼ .0002) was calculated (Figure 1). Sensitivity
and speciﬁcity for S100A8 were 60% and 88%, respectively.
S100A9 short was detected in 20 patients in the group
with GVHD (mean value, 9  108; SD, 1.6  109), in 9 patients
in the group without GVHD (mean value, 6  108; SD,
1.7 109), and in 8 healthy controls (mean value, 6 107; SD,
7.9 107), with statistically signiﬁcant differences in terms of
frequency (P ¼ .01) and levels of detection (P ¼ .002)
Figure 2. Levels of S100A9 short isoform for the 3 groups, expressed as XIC
peak area.
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87% and 47%, respectively.
S100A7 (varD27) was detected in 11 of the 23 patients
with GVHD, with a mean XIC peak area value of 7.03  108
(SD, 1.4  108), but was not detected in any patients in the
other 2 groups, for a statistically signiﬁcant difference in
terms of frequency (P ¼ .0001). Sensitivity and speciﬁcity for
S100A7 were 48% and 100%, respectively. No statistically
signiﬁcant differences in the S100A9 long and S100A12
proteins were seen among the 5 study groups.
DISCUSSION
Allo-HSCT is frequently complicated by severe infections
and GVHD. Between 35% and 70% of patients develop GVHD
after allo-HSCT, depending on the type of transplantation,
immunosuppressive treatment, and underlying diseases.
Currently, aGVHD is diagnosed based mainly on clinical
parameters, such as skin rash, diarrhea, and elevated serum
liver enzymes. To date, there is no validated diagnostic test
for aGVHD; thus, differential diagnosis of GVHD depends on
organ biopsy analysis to distinguish it from other common
complications after allo-HSCT.
Saliva contains many components of adaptive and innate
immune response crucial for local host defenses. Change in
salivary constituents could reﬂect systemic processes
occurring after allo-HSCT, such as immune reconstitution
and development of GVHD. Imanguli et al. [23] reported
increased levels of lactoferrin, secretory leukocyte protease
inhibitor, and b2-microglobulin after allo-HSCT, whereas
Dens et al. [22] found decreased levels of secretory IgA.
Nagler and Nagler [21] reported higher Ig levels in patients
with oral chronic GVHD. Bassim et al. [24] identiﬁed
decreased levels of lactotransferrin and lactoperoxidase in
the saliva of patients with oral GVHD.
Given the advantages of saliva over plasma, including low
cost, noninvasiveness, easy sample collection, easy sample
processing, and fewer proteins, we decided to investigate
this bioﬂuid for possible biomarkers of aGVHD. We per-
formed a comparative analysis of saliva from 23 patients who
developed aGVHD after allo-HSCT, from a group of 17 allo-
HASCT recipients without aGVHD, and a group of 18
healthy volunteers. We found statistically signiﬁcant differ-
ences among the 3 groups in terms of frequency and levels of
the proteins S100A8 (P ¼ .001 and .0002, respectively),S100A9 short (P ¼ .01 and .002, respectively), and S100A7
(varD27) (P ¼ .0001).
S100 proteins are calcium-binding proteins characterized
by 2 calcium-binding EF (helix-loop-helix)-hand motifs
connected by a central hinge region. S100A8 (also known as
calgranulin A or myeloid-related protein 8) and S100A9
(calgranulin 9 or myeloid-related protein 9) are found in
granulocytes, monocytes, and early-stage macrophages.
S100A8 and S100A9 are able to form homodimers, but they
also exist as heterodimers, better known as calprotectin [39].
In the extracellular compartment, S100A8 and S100A9 are
known as damage-associated molecular pattern proteins
because they are secreted by activated phagocytes during
inﬂammatory processes. This secretion involves activation of
protein kinase C and active metabolisms of the microtubule
network. S100A8 and S100A9 induce a proinﬂammatory and
thrombogenic response in endothelial cells, which is char-
acterized by induction of proinﬂammatory cytokines and
adhesion molecules such as VCAM-1 and ICAM-1, loss of
cellecell contacts and increased permeability of endothe-
lium. S100A8 and S100A9 increased the binding afﬁnity of
the integrin receptors CD11c and CD18 on neutrophil gran-
ulocytes, favoring leukocyte extravasation during inﬂam-
mation, and also acted as an endogenous Toll-like receptor-4
ligand involved in amplifying the effects of lipopolysaccha-
ride on phagocytes [40].
There is evidence of the release of S100A8 and S100A9 in
synovial ﬂuid of patients affected by autoimmune diseases,
such as rheumatoid arthritis; in stool of patients with
inﬂammatory bowel disease, in which calprotectin is used as
a biomarker for diagnosis and monitoring disease activity;
and in the saliva of patients with Sjogren syndrome
[31,32,41-43]. Our ﬁndings are interesting for several
reasons. First, although the S100 protein family has been
studied extensively, these proteins were detected in saliva
samples in patients with periodontitis, head and neck
squamous cell carcinomas, and Sjogren syndrome, as well as
in preterm neonates, only recently [31,32,35,44,45]. More-
over, the discovery of elevated S100A protein levels in the
saliva of patients with GVHD may be explained by the these
proteins’ contributions to ampliﬁcation of inﬂammatory
processes.
In this context, it is even more interesting that S100A7
was detected only in the group of patients who developed
GVHD. S1000A7was identiﬁed almost 2 decades ago, when it
was named “psoriasin” because it is overexpressed by
psoriatic keratinocytes [46]. Human psoriasin is a potent and
selective chemotactic inﬂammatory protein for CD4þ T
lymphocytes [47], which are crucial in the pathogenesis of
GVHD.
To conﬁrm our data and to clarify the role of S100 proteins
in both allo-HSCT and GVHD, evaluating their expression in
a larger cohort of subjects will be necessary. In such studies,
standardizing study populations according to disease,
conditioning regimens, and GVHD prophylaxis will be useful
to minimize possible confounding factors.
CONCLUSION
In view of the exclusive presence of S100A8 and S100A7
proteins in the saliva of patients with GVHD, we can
hypothesize that these proteins can serve as an index of
GVHD activity for use in early diagnosis, monitoring response
to therapy, or prognosis. Obviously, more data on a larger
number of patients are needed to validate this assay as a tool
for these purposes.
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